Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients
- 20 March 2021
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 27 (3) , 408-416
Abstract
Background Extended half‐life (EHL) factor VIII (FVIII) products may decrease the burden of prophylactic treatment in haemophilia A by reducing infusion frequency. However, these products still exhibit wide inter‐patient variability and benefit from pharmacokinetic (PK) tailoring. Objective Identify limited sampling strategies for rFVIIIFc, an EHL FVIII product, that produce accurate estimates of PK parameters and relevant troughs. Methods We performed a limited sampling analysis on simulated populations of adults, adolescents, and children based on published population PK data. Sampling strategies were evaluated by comparing the error in estimates of half‐life, clearance, and trough levels, to a full 6‐sample design. Furthermore, we assessed the impact of incorporating knowledge about prior doses, and the day of the PK study within the regimen. We also evaluated the potential inappropriate dose adjustment rate (IDAR) among the modelled sampling strategies. Results Many sampling strategies, including several 2‐sample designs, accurately predicted the PK and exposure measures (median absolute error 20% to ~5% for adults/adolescents. In this same scenario, appropriate scheduling of the PK study decreases likelihood of unmeasurable predose samples, reducing median error on the 72‐h trough from 25% to <12% in the youngest population. Conclusions The PK of rFVIIIFc can be accurately estimated using only peak and trough samples, provided that knowledge of prior doses is incorporated and the PK study is planned on an appropriate day within the dosing regimen.Keywords
Funding Information
- American Lebanese Syrian Associated Charities
- Center for Strategic Scientific Initiatives, National Cancer Institute (CA21765)
- Canadian Institutes of Health Research
This publication has 15 references indexed in Scilit:
- Efmoroctocog Alfa: A Review in Haemophilia ADrugs, 2016
- Predictors of non‐adherence to prescribed prophylactic clotting‐factor treatment regimens among adolescent and young adults with a bleeding disorderHaemophilia, 2016
- Challenges in the management of haemophilia on transition from adolescence to adulthoodEuropean Journal of Haematology, 2015
- Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia AJournal of Thrombosis and Haemostasis, 2015
- Population pharmacokinetics of recombinant factor VIII Fc fusion proteinClinical Pharmacology in Drug Development, 2014
- Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia ABlood, 2014
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia AHaemophilia, 2010
- A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia ATherapeutic Drug Monitoring, 2007
- Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophiliaHaemophilia, 2006